Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $28.0 million.

  • Ultragenyx Pharmaceutical's Other Operating Expenses rose 3315.73% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 3431.04%. This contributed to the annual value of $76.7 million for FY2024, which is 6971.84% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Other Operating Expenses stood at $28.0 million for Q3 2025, which was up 3315.73% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Other Operating Expenses ranged from a high of $28.7 million in Q1 2025 and a low of $3.1 million during Q2 2021
  • Moreover, its 5-year median value for Other Operating Expenses was $11.0 million (2023), whereas its average is $12.9 million.
  • Over the last 5 years, Ultragenyx Pharmaceutical's Other Operating Expenses had its largest YoY gain of 24810.16% in 2021, and its largest YoY loss of 3597.88% in 2021.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Operating Expenses (Quarter) stood at $3.5 million in 2021, then skyrocketed by 51.58% to $5.3 million in 2022, then skyrocketed by 126.57% to $12.1 million in 2023, then surged by 40.19% to $16.9 million in 2024, then surged by 65.69% to $28.0 million in 2025.
  • Its Other Operating Expenses stands at $28.0 million for Q3 2025, versus $23.0 million for Q2 2025 and $28.7 million for Q1 2025.